Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review

被引：1
|
作者：
Wang, Wei [1 ,2 ]
Wu, Jiayi [1 ,3 ]
Chen, Keyu [1 ,3 ]
Wang, Xiaojia [1 ]
Shao, Xiying [1 ]
机构：
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol,Breast Canc, 1 Banshandong Rd, Hangzhou, Peoples R China
[2] Wenzhou Med Univ, Dept Clin Med, Wenzhou, Peoples R China
[3] Zhejiang Chinese Med Univ, Dept Clin Med, Hangzhou, Peoples R China
来源：
TECHNOLOGY IN CANCER RESEARCH & TREATMENT | 2023年 / 22卷
关键词：
breast cancer; palbociclib; CDK4; 6; inhibitor; prognostic parameters; LETROZOLE;
D O I：
10.1177/15330338231173504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent studies have demonstrated that the combination of Cyclin-Dependent Kinase 4/6 Inhibitor (CDK4/6i) and endocrine therapy (ET) is more effective than ET alone and significantly improves progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) breast cancer (BC). Palbociclib is the first CDK4/6i approved for use, and its clinical advantages have been shown. However, 30% of patients will continue to develop secondary drug resistance. Therefore, exploring the parameters that can predict the efficacy of Palbociclib and developing a clinical prediction model is essential for evaluating the prognosis of patients.
引用
收藏
页数：9
相关论文
共 50 条
  • [11] Palbociclib versus abemaciclib in HR+/HER2-advanced breast cancer: an indirect comparison of patient-reported end points
    Law, Ernest
    Gavanji, Roya
    Walsh, Sarah
    Haltner, Anja
    McTavish, Rebecca
    Cameron, Chris
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 11 (02) : 109 - 120
  • [12] Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study
    Mycock, Katie
    Zhan, Lin
    Hart, Kieran
    Taylor-Stokes, Gavin
    Milligan, Gary
    Atkinson, Christian
    Mitra, Debanjali
    FUTURE ONCOLOGY, 2021, 18 (03) : 349 - 362
  • [13] Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer
    Dieras, Veronique
    Rugo, Hope S.
    Schnell, Patrick
    Gelmon, Karen
    Cristofanilli, Massimo
    Loi, Sherene
    Colleoni, Marco
    Lu, Dongrui R.
    Mori, Ave
    Gauthier, Eric
    Huang Bartlett, Cynthia
    Slamon, Dennis J.
    Turner, Nicholas C.
    Finn, Richard S.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2019, 111 (04): : 419 - 430
  • [14] Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review
    Christiansen, Emilie Adrian
    Kuemler, Iben
    FUTURE SCIENCE OA, 2024, 10 (01):
  • [15] Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2-advanced breast cancer: a review
    Freedman, Rachel A.
    Tolaney, Sara M.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (03) : 607 - 614
  • [16] Efficacy and Safety of Cyclin-Dependent Kinases 4 and 6 Inhibitors in HR+/HER2-Advanced Breast Cancer
    Xie, Ning
    Qin, Tao
    Ren, Wei
    Yao, Herui
    Yu, Yunfang
    Hong, Huangming
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 4241 - 4250
  • [17] Ribociclib for post-menopausal women with HR+/HER2-advanced or metastatic breast cancer
    Zangardi, Mark L.
    Spring, Laura M.
    Blouin, Gayle C.
    Bardia, Aditya
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (11) : 1169 - 1176
  • [18] Palbociclib in a patient with HR+/HER2- advanced breast cancer and HIV1 infection: a case report
    Canino, Fabio
    Moscetti, Luca
    Borghi, Vanni
    Dominici, Massimo
    Piacentini, Federico
    BREAST CANCER MANAGEMENT, 2021, 10 (04)
  • [19] Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2-advanced breast cancer: final results from the POLARIS trial
    Tripathy, Debu
    Blum, Joanne L.
    Karuturi, Meghan S.
    Mccune, Steven
    Kurian, Sobha
    Moezi, Mehdi
    Anderson, Daniel
    Gauthier, Eric
    Zhang, Zhe
    Montelongo, Monica Z.
    Wang, Yao
    Rocque, Gabrielle B.
    ONCOLOGIST, 2024,
  • [20] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
    Kim, Esther S.
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2017, 12 (03) : 373 - 383
12345